Provided by Tiger Trade Technology Pte. Ltd.

BioCardia

1.45
+0.02001.40%
Post-market: 1.450.00000.00%17:55 EST
Volume:46.55K
Turnover:67.62K
Market Cap:15.39M
PE:-0.87
High:1.47
Open:1.45
Low:1.43
Close:1.43
52wk High:3.20
52wk Low:1.00
Shares:10.61M
Float Shares:4.05M
Volume Ratio:0.61
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6599
EPS(LYR):-2.8960
ROE:-317.47%
ROA:-86.45%
PB:5.86
PE(LYR):-0.50

Loading ...

BRIEF-Biocardia Announces Election Of New Board Director

Reuters
·
Dec 03

BioCardia Appoints Marvin Slosman to Board as Richard Krasno Departs

Reuters
·
Dec 03

Press Release: BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

Dow Jones
·
Dec 03

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

GlobeNewswire
·
Dec 01

BioCardia Appoints New VP of Quality

TIPRANKS
·
Nov 25

BioCardia Strengthens Leadership Team With the Addition of Farhan Shahab as Vice President of Quality

THOMSON REUTERS
·
Nov 24

Press Release: BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Dow Jones
·
Nov 24

BioCardia, Inc. Q3 Net Income USD -1.483 Million

Reuters
·
Nov 20

BioCardia’s Earnings Call: Progress Amid Financial Challenges

TIPRANKS
·
Nov 14

BioCardia’s Q3 2025: Clinical Progress and Financial Stability

TIPRANKS
·
Nov 13

Cellular therapy developer BioCardia's Q3 net loss narrows

Reuters
·
Nov 13

BRIEF-BioCardia, Inc. Q3 Net Income USD -1.483 Million

Reuters
·
Nov 13

BioCardia, Inc. Q3 Operating Income USD -1.488 Million

THOMSON REUTERS
·
Nov 13

BioCardia, Inc. Q3 Basic EPS USD -0.24

THOMSON REUTERS
·
Nov 13

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

GlobeNewswire
·
Nov 13

BioCardia reports Q3 net loss of $1.5 million on increased R&D expenses

Reuters
·
Nov 13

BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate

Benzinga
·
Nov 13

BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 Cardiamp HF Ii Cell Therapy Pivotal Trial

THOMSON REUTERS
·
Nov 10

BioCardia Enrolls First Patient in Phase 3 CardiAMP HF II Heart Failure Trial

Reuters
·
Nov 10

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

GlobeNewswire
·
Nov 06